{"id":"ethinyl-estradiol-norgestimate-oral-tablet","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Breast tenderness"},{"rate":"5-10","effect":"Breakthrough bleeding"},{"rate":"5","effect":"Mood changes"},{"rate":"0.3-0.4","effect":"Venous thromboembolism"}]},"_chembl":{"chemblId":"CHEMBL3544698","moleculeType":"Small molecule","molecularWeight":"312.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ethinyl estradiol is a synthetic estrogen that provides negative feedback on the hypothalamic-pituitary-ovarian axis, while norgestimate is a progestin that further suppresses LH surge and alters cervical mucus and endometrial environment. Together, these hormones prevent ovulation and create an inhospitable environment for sperm and embryo implantation.","oneSentence":"This combination oral contraceptive suppresses ovulation by inhibiting gonadotropin-releasing hormone, preventing follicle-stimulating hormone and luteinizing hormone surges.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:23.909Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception (prevention of pregnancy)"},{"name":"Acne vulgaris (FDA-approved indication for certain formulations)"}]},"trialDetails":[{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT07305831","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-22","conditions":"Healthy","enrollment":62},{"nctId":"NCT07074327","phase":"PHASE1","title":"Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-07-11","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":74},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360},{"nctId":"NCT07378579","phase":"PHASE1","title":"An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001","status":"COMPLETED","sponsor":"Alumis Inc","startDate":"2024-06-21","conditions":"Healthy Volunteer","enrollment":52},{"nctId":"NCT07272629","phase":"PHASE1","title":"A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-12-04","conditions":"Cardiac Repolarization, Healthy Volunteers","enrollment":44},{"nctId":"NCT06294600","phase":"PHASE3","title":"Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)","status":"RECRUITING","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2024-02-12","conditions":"Community-acquired Pneumonia","enrollment":330},{"nctId":"NCT06107036","phase":"PHASE1","title":"A Study in Healthy People to Test Whether Different Doses of BI 1015550 Have Potential to Induce Heart Rhythm Abnormalities","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-03-06","conditions":"Healthy","enrollment":46},{"nctId":"NCT06411860","phase":"PHASE1","title":"A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants","status":"COMPLETED","sponsor":"Amgen","startDate":"2024-09-12","conditions":"Basic Science","enrollment":32},{"nctId":"NCT04255277","phase":"PHASE1","title":"To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.","status":"COMPLETED","sponsor":"Viatris Innovation GmbH","startDate":"2020-01-31","conditions":"Healthy Subjects","enrollment":97},{"nctId":"NCT07162116","phase":"PHASE1","title":"A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants","status":"RECRUITING","sponsor":"Shijiazhuang Yiling Pharmaceutical Co. Ltd","startDate":"2025-07-06","conditions":"Acute Myeloid Leukemia With FLT3/ITD Mutation","enrollment":45},{"nctId":"NCT03479736","phase":"","title":"A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-20","conditions":"Retinal Detachment, Achilles Tendon, Aneurysm, Dissecting","enrollment":117911},{"nctId":"NCT06820307","phase":"PHASE1","title":"Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-02-25","conditions":"Pain","enrollment":50},{"nctId":"NCT03494907","phase":"PHASE1","title":"A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-09","conditions":"Healthy","enrollment":52},{"nctId":"NCT05893862","phase":"PHASE1","title":"A Study To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia (MK-8189-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-06-26","conditions":"Schizophrenia","enrollment":107},{"nctId":"NCT04175808","phase":"PHASE1","title":"Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults","status":"COMPLETED","sponsor":"Cytokinetics","startDate":"2019-11-14","conditions":"QT Intervals Changes, QTc Intervals Changes","enrollment":70},{"nctId":"NCT04873323","phase":"PHASE1","title":"A QT/QTc Evaluation Study of TS-142 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Taisho Pharmaceutical Co., Ltd.","startDate":"2021-06-07","conditions":"Healthy Subjects","enrollment":59},{"nctId":"NCT05400369","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2022-08-10","conditions":"COPD Exacerbation Acute","enrollment":140},{"nctId":"NCT06589726","phase":"PHASE1","title":"A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2024-09-10","conditions":"Healthy","enrollment":40},{"nctId":"NCT05580003","phase":"PHASE1","title":"A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-10-17","conditions":"Healthy","enrollment":94},{"nctId":"NCT06462326","phase":"PHASE1","title":"A Study to Compare the Effect of Omadacycline Versus Moxifloxacin in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Zai Lab (Hong Kong), Ltd.","startDate":"2024-04-16","conditions":"Healthy Volunteer","enrollment":24},{"nctId":"NCT06591845","phase":"PHASE1","title":"Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Ark Biopharmaceutical Co., Ltd.","startDate":"2024-09-15","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT05830071","phase":"PHASE1","title":"A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-03-29","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":95},{"nctId":"NCT04953923","phase":"PHASE1","title":"Thorough QT Assessment of Cedazuridine in Healthy Subjects","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2021-07-01","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT06310876","phase":"PHASE1","title":"A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects","status":"COMPLETED","sponsor":"Calico Life Sciences LLC","startDate":"2024-03-14","conditions":"Healthy","enrollment":72},{"nctId":"NCT04828824","phase":"PHASE4","title":"Premature Discontinuation of Contraceptive Implants","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-06-18","conditions":"Contraception Behavior","enrollment":600},{"nctId":"NCT05508776","phase":"PHASE1","title":"A Trial to Evaluate the Effect of LEO 152020 on the Heart of Healthy People","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2022-09-16","conditions":"Healthy Volunteers, Cardiac Repolarisation","enrollment":28},{"nctId":"NCT04821063","phase":"PHASE1","title":"Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval","status":"COMPLETED","sponsor":"Italfarmaco","startDate":"2021-04-13","conditions":"Duchenne and Becker Muscular Dystrophy, Polycytemia Vera","enrollment":31},{"nctId":"NCT05924815","phase":"PHASE1","title":"Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval","status":"COMPLETED","sponsor":"Cytokinetics","startDate":"2023-05-15","conditions":"Healthy Participants","enrollment":44},{"nctId":"NCT04724044","phase":"PHASE3","title":"Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia","status":"COMPLETED","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2021-01-25","conditions":"Community-acquired Pneumonia, Sepsis, Inflammatory Response","enrollment":278},{"nctId":"NCT05933447","phase":"PHASE1","title":"Thorough QT Study to Evaluate the Effect of Rodatristat Ethyl, Rodatristat and Its Major Metabolites on the Heart","status":"COMPLETED","sponsor":"Altavant Sciences GmbH","startDate":"2023-05-12","conditions":"Healthy","enrollment":27},{"nctId":"NCT05905484","phase":"PHASE1","title":"Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2023-04-25","conditions":"Healthy Volunteer Study","enrollment":35},{"nctId":"NCT05841160","phase":"PHASE1","title":"Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization","status":"COMPLETED","sponsor":"Emalex Biosciences Inc.","startDate":"2023-03-15","conditions":"QT/QTc","enrollment":29},{"nctId":"NCT01322139","phase":"PHASE1","title":"Sativex Thorough QT/QTc Study","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2007-12","conditions":"Effects of Sativex on ECG","enrollment":258},{"nctId":"NCT05668936","phase":"PHASE1","title":"A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2023-01-03","conditions":"Non-alcoholic Steatohepatitis","enrollment":31},{"nctId":"NCT05355935","phase":"PHASE1","title":"A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2022-04-27","conditions":"Healthy Volunteer","enrollment":48},{"nctId":"NCT04172987","phase":"PHASE1","title":"A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-02-26","conditions":"Healthy","enrollment":40},{"nctId":"NCT04281342","phase":"PHASE1","title":"To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2020-01-14","conditions":"Healthy Subjects","enrollment":48},{"nctId":"NCT05027893","phase":"NA","title":"Complications After Lower Third Molar Surgery","status":"UNKNOWN","sponsor":"University of Novi Sad","startDate":"2019-06-07","conditions":"Postoperative Complications, Antibiotic Reaction, Antibiotic Side Effect","enrollment":157},{"nctId":"NCT05192369","phase":"PHASE1","title":"A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers","status":"COMPLETED","sponsor":"Concert Pharmaceuticals","startDate":"2022-01-04","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT00779532","phase":"PHASE1","title":"Thorough QT/QTc Study of Multiple Oral Doses of NOMAC-E2 (Org 10486 0 + Org 2317) in Healthy Women (Study 292011)(P05802)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-05","conditions":"Contraception","enrollment":189},{"nctId":"NCT04966325","phase":"EARLY_PHASE1","title":"Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"LG Chem","startDate":"2021-09-23","conditions":"Hyperuricemia, Gout, Qt Interval, Variation in","enrollment":37},{"nctId":"NCT01941446","phase":"PHASE1","title":"A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization","status":"COMPLETED","sponsor":"Tetraphase Pharmaceuticals, Inc","startDate":"2013-03","conditions":"Normal Healthy Subjects","enrollment":54},{"nctId":"NCT05016206","phase":"PHASE1","title":"A Study of the Cardiac Effects of Danicopan in Healthy Adults","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-07-26","conditions":"Healthy","enrollment":33},{"nctId":"NCT00789568","phase":"PHASE1","title":"A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects","status":"COMPLETED","sponsor":"BioMarin Pharmaceutical","startDate":"2008-10","conditions":"Phenylketonuria","enrollment":56},{"nctId":"NCT04126343","phase":"PHASE1","title":"A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants","status":"TERMINATED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2019-10-23","conditions":"Healthy Study Participants","enrollment":54},{"nctId":"NCT04898907","phase":"PHASE1","title":"Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval","status":"UNKNOWN","sponsor":"Angion Biomedica Corp","startDate":"2021-06","conditions":"Healthy Volunteer","enrollment":48},{"nctId":"NCT04867980","phase":"PHASE1","title":"A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2016-04-01","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT03489005","phase":"PHASE1","title":"Effect of BIA 5 1058 on Cardiac Repolarization","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2018-04-09","conditions":"Cardiovascular Disease, Pulmonary Arterial Hypertension, Heart Failure","enrollment":49},{"nctId":"NCT02533427","phase":"PHASE1","title":"Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-10-29","conditions":"HCV Infection","enrollment":15},{"nctId":"NCT03516630","phase":"PHASE1","title":"Effects of Three Single Oral Doses of Trazodone on the QTc Interval Duration in Healthy Volunteers","status":"COMPLETED","sponsor":"Aziende Chimiche Riunite Angelini Francesco S.p.A","startDate":"2017-03-20","conditions":"Healthy","enrollment":20},{"nctId":"NCT02679573","phase":"PHASE3","title":"Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2016-12-14","conditions":"Community Acquired Bacterial Pneumonia","enrollment":860},{"nctId":"NCT04019574","phase":"PHASE1","title":"Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects","status":"COMPLETED","sponsor":"Cara Therapeutics, Inc.","startDate":"2019-06-20","conditions":"Healthy","enrollment":57},{"nctId":"NCT01986894","phase":"PHASE1","title":"A Phase 1 QT Study in Healthy Male Subjects","status":"COMPLETED","sponsor":"Celgene","startDate":"2013-10-18","conditions":"Clinical Pharmacology, Healthy Volunteer Study","enrollment":72},{"nctId":"NCT04083833","phase":"PHASE1","title":"A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Wex Pharmaceuticals Inc.","startDate":"2018-02-07","conditions":"TQT Study","enrollment":25},{"nctId":"NCT03985410","phase":"PHASE1","title":"Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers","status":"COMPLETED","sponsor":"Entasis Therapeutics","startDate":"2019-05-23","conditions":"Acinetobacter Baumannii-calcoaceticus Complex Infections","enrollment":32},{"nctId":"NCT02193776","phase":"PHASE2","title":"A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2014-10-23","conditions":"Tuberculosis","enrollment":240},{"nctId":"NCT04019652","phase":"PHASE1","title":"The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2015-11-19","conditions":"Hypertension, Mineralocorticoid Receptor Antagonist","enrollment":55},{"nctId":"NCT02922348","phase":"PHASE3","title":"Hormone Replacement for Premature Ovarian Insufficiency","status":"WITHDRAWN","sponsor":"University of Pennsylvania","startDate":"2016-03-01","conditions":"Primary Ovarian Insufficiency","enrollment":""},{"nctId":"NCT03951402","phase":"PHASE1","title":"Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2003-03","conditions":"Prolonged QTc Interval, Pharmacokinetic","enrollment":48},{"nctId":"NCT02080468","phase":"PHASE1","title":"Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2014-02-19","conditions":"Healthy","enrollment":32},{"nctId":"NCT02785770","phase":"PHASE1","title":"A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-06-29","conditions":"Healthy","enrollment":44},{"nctId":"NCT02792517","phase":"PHASE1","title":"Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-02-12","conditions":"Headache, Migraine","enrollment":41},{"nctId":"NCT01461460","phase":"PHASE1","title":"A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects","status":"COMPLETED","sponsor":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2011-11-28","conditions":"Healthy Volunteer","enrollment":48},{"nctId":"NCT03405168","phase":"PHASE2","title":"Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2018-01-01","conditions":"Advanced Breast Cancer, Antibiotic, Stable Disease With a Trend of Progression","enrollment":35},{"nctId":"NCT01475513","phase":"PHASE4","title":"Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2011-11","conditions":"Insulin Sensitivity, Cardiovascular Risk, Perimenopausal Disorder","enrollment":47},{"nctId":"NCT00205504","phase":"PHASE4","title":"Oral Contraceptives in the Metabolic Syndrome","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2005-06","conditions":"Metabolic Syndrome X, Insulin Resistance, Obesity","enrollment":46},{"nctId":"NCT02293148","phase":"PHASE1","title":"Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-11-17","conditions":"Anaemia","enrollment":61},{"nctId":"NCT02157467","phase":"PHASE1","title":"Study of Combined Oral Contraceptive Effects in Female Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-06-02","conditions":"Infection, Human Immunodeficiency Virus","enrollment":46},{"nctId":"NCT02737605","phase":"PHASE1","title":"A Study to Evaluate the Effects of Esketamine on Cardiac Repolarization in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-07-01","conditions":"Healthy","enrollment":62},{"nctId":"NCT03362853","phase":"PHASE1","title":"A Study Evaluating the Effect of a Single-dose Oral Administration of Nemonoxacin Capsule on QTc Intervals and Heart Rhythms of Healthy Subjects and the Influence of Food Intake on QTc Intervals and Pharmacokinetic Characteristics","status":"COMPLETED","sponsor":"TaiGen Biotechnology Co., Ltd.","startDate":"2012-06-25","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT03164109","phase":"PHASE1","title":"A Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy Volunteers","status":"COMPLETED","sponsor":"Galera Therapeutics, Inc.","startDate":"2017-08-18","conditions":"Healthy Volunteers, Healthy","enrollment":28},{"nctId":"NCT03155893","phase":"PHASE1","title":"A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-05-12","conditions":"Healthy","enrollment":59},{"nctId":"NCT01449188","phase":"PHASE1","title":"To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-08-16","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":60},{"nctId":"NCT02257398","phase":"PHASE1","title":"Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-06","conditions":"Infections, Respiratory Tract","enrollment":55},{"nctId":"NCT01521377","phase":"PHASE1","title":"QTc Study GSK573719+GW642444","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-12-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":100},{"nctId":"NCT01702376","phase":"PHASE1","title":"This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-03","conditions":"Obstetric Labour, Premature","enrollment":52},{"nctId":"NCT01406262","phase":"PHASE1","title":"Albiglutide Thorough ECG Study in Healthy Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-06","conditions":"Diabetes Mellitus, Type 2","enrollment":94},{"nctId":"NCT01209026","phase":"PHASE1","title":"Corrected QT (QTc) Study With Flucticasone Furoate and GW642444","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-23","conditions":"Asthma","enrollment":85},{"nctId":"NCT02213029","phase":"PHASE1","title":"A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2014-08-28","conditions":"Embryo Transfer","enrollment":33},{"nctId":"NCT00775190","phase":"NA","title":"Side Effect Profiles of Brand Name Versus Generic Oral Contraceptives","status":"TERMINATED","sponsor":"Corewell Health East","startDate":"2008-10","conditions":"Contraception","enrollment":12},{"nctId":"NCT02924337","phase":"PHASE1","title":"Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects","status":"COMPLETED","sponsor":"Poxel SA","startDate":"2016-09","conditions":"Qt Interval, Variation in","enrollment":55},{"nctId":"NCT02508753","phase":"PHASE1","title":"Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2010-06","conditions":"Healthy","enrollment":52},{"nctId":"NCT01787357","phase":"PHASE1","title":"A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-06","conditions":"Healthy","enrollment":60},{"nctId":"NCT02479308","phase":"PHASE1","title":"A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2015-06","conditions":"Healthy","enrollment":129},{"nctId":"NCT02217930","phase":"PHASE1","title":"Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers","status":"COMPLETED","sponsor":"Wockhardt","startDate":"2014-08","conditions":"Qt Interval, Variation in","enrollment":80},{"nctId":"NCT00983957","phase":"PHASE1","title":"Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-10","conditions":"Chronic Hepatitis C","enrollment":47},{"nctId":"NCT01073891","phase":"PHASE1","title":"Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-05","conditions":"Healthy","enrollment":24},{"nctId":"NCT01790087","phase":"PHASE1","title":"ANX-188 Thorough QT/QTc Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Mast Therapeutics, Inc.","startDate":"2013-02","conditions":"Healthy","enrollment":72},{"nctId":"NCT01039610","phase":"PHASE1","title":"A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2009-11","conditions":"Infections, Bacterial","enrollment":""},{"nctId":"NCT02091310","phase":"PHASE1","title":"Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers","status":"COMPLETED","sponsor":"Genfit","startDate":"2014-02","conditions":"Healthy Volunteers","enrollment":200},{"nctId":"NCT00672399","phase":"PHASE1","title":"Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Healthy Subjects","enrollment":70},{"nctId":"NCT01511029","phase":"PHASE1","title":"Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)","status":"COMPLETED","sponsor":"Knopp Biosciences","startDate":"2012-01","conditions":"Amyotrophic Lateral Sclerosis","enrollment":68},{"nctId":"NCT00717561","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-02","conditions":"Pneumonia","enrollment":60},{"nctId":"NCT01325415","phase":"PHASE1","title":"A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-04","conditions":"Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle","enrollment":45},{"nctId":"NCT01658020","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg","status":"COMPLETED","sponsor":"Dong Wha Pharmaceutical Co. Ltd.","startDate":"2012-08","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":345},{"nctId":"NCT01487135","phase":"PHASE1","title":"Phase 1 Study to Assess the Effects of EVP-6124 on the QT/QTc Interval in Healthy Subjects","status":"COMPLETED","sponsor":"FORUM Pharmaceuticals Inc","startDate":"2011-12","conditions":"Healthy Subjects, Cardiac Repolarization","enrollment":60},{"nctId":"NCT02127593","phase":"PHASE1","title":"A Bioequivalence Study of Norgestimate /Ethinyl Estradiol (NGM/EE) Tablets Manufactured at 2 Different Facilities","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-06","conditions":"Healthy","enrollment":101},{"nctId":"NCT02040987","phase":"PHASE1","title":"AZD3293 Thorough QT Study in Healthy Male Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-01","conditions":"Alzheimer's Disease","enrollment":52},{"nctId":"NCT02027454","phase":"PHASE1","title":"Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-01","conditions":"Infection, Human Immunodeficiency Virus","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ethinyl Estradiol / Norgestimate Oral Tablet","genericName":"Ethinyl Estradiol / Norgestimate Oral Tablet","companyName":"University of Colorado, Denver","companyId":"university-of-colorado-denver","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination oral contraceptive suppresses ovulation by inhibiting gonadotropin-releasing hormone, preventing follicle-stimulating hormone and luteinizing hormone surges. Used for Contraception (prevention of pregnancy), Acne vulgaris (FDA-approved indication for certain formulations).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}